Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
Prostate cancer was used as a paradigm because this tumor type is reliant at all stages of the disease on androgen receptor (AR) signaling, and cyclin D1 has been shown to negatively modulate AR-dependent expression of prostate-specific antigen (KLK3/PSA).
|
21212260 |
2011 |
Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
Cyclin D1 repressor domain mediates proliferation and survival in prostate cancer.
|
19079343 |
2009 |
Malignant neoplasm of prostate
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Cyclin D1 splice variants: polymorphism, risk, and isoform-specific regulation in prostate cancer.
|
19706803 |
2009 |
Malignant neoplasm of prostate
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Cyclin D1 protein was expressed at relatively high levels in all of the six human prostate cancer cell lines examined, but was not detected in the cultures of normal human prostate cells.
|
9568672 |
1998 |
Malignant neoplasm of prostate
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
A clinicopathological study of p53, p21 (WAF1/CIP1) and cyclin D1 expression in human prostate cancers.
|
9873247 |
1998 |
Malignant neoplasm of prostate
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
As a result, the CCND1-RNASEL-CDKN1A-TP73-MDM2-UBE2I axis was identified as a bottleneck in the miRNA-mediated gene expression regulatory network of PCa according to network topological analysis.
|
29467540 |
2018 |
Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
Collectively, our findings suggest that the hormone-mediated recruitment of cyclin D1 to sites of DDR may facilitate the resistance of prostate cancer cells to DNA damage therapies and highlight the need to explore other therapeutic approaches in prostate cancer to prevent or overcome drug resistance.
|
26582866 |
2016 |
Malignant neoplasm of prostate
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Concomitantly, BBP treatment decreased the protein levels of phosphorylated retinoblastoma, cyclin D1 and E, cyclin-dependent kinase (CDK) 4 and 2, and pre-replication complex (CDC6 and MCM7) in LNCaP and PC-3 cells, whereas CDK inhibitor p27 was elevated in these cell lines.
|
22067725 |
2012 |
Malignant neoplasm of prostate
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Enforced expression of microRNA-590-3p led to repression of inositol polyphosphate 4-phosphatase type II messenger RNA and protein expression, as well as upregulation of p-Akt, p-FoxO3a, and cyclin D1 and downregulation of p21 expression in prostate cancer cell lines.
|
28345464 |
2017 |
Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
RGD |
Exisulind in combination with celecoxib modulates epidermal growth factor receptor, cyclooxygenase-2, and cyclin D1 against prostate carcinogenesis: in vivo evidence.
|
17908994 |
2007 |
Malignant neoplasm of prostate
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Expression of miR-124, STAT3, p-STAT3, Bcl-2 and Cyclin D1 was compared between normal human prostate epithelial cell RWPE-1 and prostate cancer cell DU145.
|
28617558 |
2017 |
Malignant neoplasm of prostate
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Finally, we demonstrated that rottlerin was able to suppress the expression of cyclin D1 and survivin, two targets of both Wnt/β-catenin and mTORC1 signaling, in prostate and breast cancer cells, and displayed remarkable anticancer activity with IC(50) values between 0.7 and 1.7 μM for prostate cancer PC-3 and DU145 cells and breast cancer MDA-MB-231 and T-47D cells.
|
24607787 |
2014 |
Malignant neoplasm of prostate
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Galectin-3 knockdown in human prostate cancer PC3 cells led to cell-cycle arrest at G(1) phase, up-regulation of nuclear p21, and hypophosphorylation of the retinoblastoma tumor suppressor protein (pRb), with no effect on cyclin D1, cyclin E, cyclin-dependent kinases (CDK2 and CDK4), and p27 protein expression levels.
|
19286570 |
2009 |
Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
Here, our aim was to determine if miR-193b targets cyclin D1 in prostate cancer.
|
26129688 |
2015 |
Malignant neoplasm of prostate
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Here, we demonstrate that RCN1 is overexpressed in clinical prostate cancer (PCa) samples, associated with cyclin B, not cyclin D1 expression, compared to that of benign tissues in a Chinese Han population.
|
29453900 |
2018 |
Malignant neoplasm of prostate
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Here, we identified microRNA-16-5p(miR-16-5p) is significantly upregulated in CaP LNCaP cells following IR and can enhance radiosensitivity through modulating Cyclin D1/E1-pRb-E2F1 pathway.
|
30536619 |
2019 |
Malignant neoplasm of prostate
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
However, the AA genotype of CCND1 showed a tendency to increase prostate cancer risk in subjects aged 70 years or older (odds ratio [OR] = 2.14, 95% confidence interval [CI] = 0.86-5.27, p = 0.096).
|
14981950 |
2004 |
Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
In conclusion, results present that SNHG7 regulates the cycle progression and acts as an oncogenic gene in the prostate cancer tumorigenesis via miR-503/Cyclin D1 pathway, revealing the vital role of lncRNA/miRNA/mRNA axis in prostate cancer carcinogenesis.
|
29571017 |
2018 |
Malignant neoplasm of prostate
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In order to investigate factors involved in human prostate cancer progression, we studied the effects of cyclin D1 overexpression on human prostate cancer cell proliferation and tumorigenicity by transfecting LNCaP cells with a retroviral vector containing human cyclin D1 cDNA.
|
9591774 |
1998 |
Malignant neoplasm of prostate
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In the present study, we investigated the diagnostic value of 3 different genes associated with CaP carcinogenesis, encoding for cell cycle (MDM2, CCND1) and apoptotic (Fas) genes that are differentially expressed in CaP.
|
20822933 |
2012 |
Malignant neoplasm of prostate
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Increased risk of prostate cancer associated with AA genotype of cyclin D1 gene A870G polymorphism.
|
12455063 |
2003 |
Malignant neoplasm of prostate
|
0.600 |
Biomarker
|
disease |
BEFREE |
Long noncoding RNA LOXL1-AS1 regulates prostate cancer cell proliferation and cell cycle progression through miR-541-3p and CCND1.
|
30278884 |
2018 |
Malignant neoplasm of prostate
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Meanwhile, the expression level of CCND1 was significantly upregulated in the PCa tissues and cell lines, which presented negative correlation with the expression of miR-487a-3p.
|
31309555 |
2020 |
Malignant neoplasm of prostate
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Mining of publicly available human prostate cancer oligoarray datasets revealed that the expression of numerous genes (e.g., CCND1, CD44) under the control of beta-catenin transcription is down-regulated.
|
20454608 |
2010 |
Malignant neoplasm of prostate
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Numerous epidemiological studies have evaluated the association between the CCND1 A870G polymorphism and the risk of prostate cancer (PCa).
|
25888980 |
2015 |